Unknown

Dataset Information

0

Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients.

ABSTRACT: The most common event responsible for resistance to first- and second-generation (1st and 2nd) epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) is acquisition of T790M mutation. We examined whether T790M is related to clinicopathologic or prognostic factors in patients with relapse of EGFR mutant non-small cell lung cancer (NSCLC) after treatment with 1st or 2nd EGFR-TKIs. We retrospectively reviewed the T790M status and clinical characteristics of 73 patients with advanced or recurrent NSCLC who had been treated with EGFR-TKIs and undergone rebiopsy at Kurume University Hospital between March 2005 and December 2015. T790M mutation was more frequent in patients with EGFR exon 19 deletion mutation (63%, 26/41) than in those with L858R mutation (38%, 12/32) (p?=?0.035). The median total duration of 1st or 2nd EGFR-TKI treatment was significantly longer in patients with T790M mutation than in those without (15.3 months vs 8.1 months, p?

SUBMITTER: Matsuo N 

PROVIDER: S-EPMC5095551 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients.

Matsuo Norikazu N   Azuma Koichi K   Sakai Kazuko K   Hattori Satoshi S   Kawahara Akihiko A   Ishii Hidenobu H   Tokito Takaaki T   Kinoshita Takashi T   Yamada Kazuhiko K   Nishio Kazuto K   Hoshino Tomoaki T  

Scientific reports 20161104

The most common event responsible for resistance to first- and second-generation (1st and 2nd) epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) is acquisition of T790M mutation. We examined whether T790M is related to clinicopathologic or prognostic factors in patients with relapse of EGFR mutant non-small cell lung cancer (NSCLC) after treatment with 1st or 2nd EGFR-TKIs. We retrospectively reviewed the T790M status and clinical characteristics of 73 patients with advance  ...[more]

Similar Datasets

Unknown The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma.
| S-EPMC5354886 | biostudies-literature
Unknown The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M.
| S-EPMC5217000 | biostudies-literature
Unknown 3D radiomics predicts EGFR mutation, exon-19 deletion and exon-21 L858R mutation in lung adenocarcinoma.
| S-EPMC7481623 | biostudies-literature
Unknown The comparison of EGFR-TKI failure modes and subsequent management between exon 19 deletion and exon 21 L858R mutation in advanced non-small-cell lung cancer.
| S-EPMC5556650 | biostudies-literature
Unknown A case of EGFR mutation-positive lung adenocarcinoma in which the T790M allele fraction was increased by repeated EGFR-TKI treatment.
| S-EPMC6823937 | biostudies-literature
Unknown AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
| S-EPMC4315625 | biostudies-literature
Unknown The EGFR T790M Mutation Is Acquired through AICDA-Mediated Deamination of 5-Methylcytosine following TKI Treatment in Lung Cancer.
| S-EPMC6295274 | biostudies-literature
Unknown Semaphorin 7A promotes EGFR-TKI resistance in EGFR mutant lung adenocarcinoma cells.
| S-EPMC6338389 | biostudies-literature
Unknown ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation.
| S-EPMC4367691 | biostudies-literature
Unknown The Presence of EGFR T790M in TKI-Naive Lung Cancer Samples of Patients Who Developed a T790M-Positive Relapse on First or Second Generation TKI Is Rare.
| S-EPMC9320221 | biostudies-literature